** U.S. listed-shares of Merus NV MRUS.O up about 3% at $46.19 premarket
** Co has entered into a U.S. commercialization agreement with private biotech Partner Therapeutics
** Under the deal, Partner will assume full rights to U.S. commercialization of MRUS' gene-targeting cancer therapy zenocutuzumab or zeno for the treatment of NRG1 fusion-positive cancer in the United States
** In exchange, MRUS will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments tied to the therapy's future annual sales
** Last month, U.S. Food and Drug Administration extended the review of zeno to allow sufficient time to assess some recent information submitted by MRUS to the agency
** Co is seeking approval for zeno, which targets the NRG1 gene associated with progression of several tumors, for treatment of hard-to-treat types of lung and pancreatic cancers
** As of last close, MRUS was up ~57% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。